Your browser doesn't support javascript.
loading
Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
Alanin, Mikkel Christian; Klausen, Camilla; Caye-Thomasen, Per; Thomsen, Carsten; Fugleholm, Kaare; Poulsgaard, Lars; Lassen, Ulrik; Mau-Sorensen, Morten; Hofland, Kenneth Francis.
Afiliación
  • Alanin MC; a Department of Otolaryngology - Head and Neck Surgery and Audiology , Copenhagen University Hospital , Copenhagen , Denmark.
  • Klausen C; b Department of Radiology , Copenhagen University Hospital , Copenhagen , Denmark.
  • Caye-Thomasen P; a Department of Otolaryngology - Head and Neck Surgery and Audiology , Copenhagen University Hospital , Copenhagen , Denmark.
  • Thomsen C; e Faculty of Health and Medical Sciences , University of Copenhagen , Copenhagen , Denmark.
  • Fugleholm K; b Department of Radiology , Copenhagen University Hospital , Copenhagen , Denmark.
  • Poulsgaard L; e Faculty of Health and Medical Sciences , University of Copenhagen , Copenhagen , Denmark.
  • Lassen U; c Department of Neurosurgery , Copenhagen University Hospital , Copenhagen , Denmark.
  • Mau-Sorensen M; c Department of Neurosurgery , Copenhagen University Hospital , Copenhagen , Denmark.
  • Hofland KF; d Department of Oncology and Radiotherapy , Copenhagen University Hospital , Copenhagen , Denmark.
Int J Neurosci ; 126(11): 1002-6, 2016 Nov.
Article en En | MEDLINE | ID: mdl-26365467
PURPOSE: The hallmark of neurofibromatosis type 2 (NF2) is bilateral vestibular schwannomas (VS). Approximately 80% of NF2 patients also have intracranial meningiomas. Vascular endothelial growth factor (VEGF) is expressed in both NF2-related and sporadic occurring meningiomas and anti-VEGF therapy (bevacizumab) may, therefore, be beneficial in NF2-related meningiomas. The purpose of the study was to report the effect of bevacizumab on meningiomas in NF2 patients. MATERIALS AND METHODS: We retrospectively reviewed the effect of bevacizumab on the cross-sectional area (CSA) of 14 intracranial meningiomas in 7 NF2 patients. Bevacizumab 10 mg/kg was administered intravenously every two weeks for six months and 15 mg/kg every three weeks thereafter. Patients were evaluated according to the modified Macdonald criteria with repeated magnetic resonance (MR) scans. RESULTS: The median duration of therapy was 27 months (range 16-34) and 42 MR scans (median 8, range 4-11) were reviewed. The median annual change in meningioma CSA prior to bevacizumab was 2% (range -4%-+76%). During treatment, a decrease in meningioma CSA was observed in 5 of 14 meningiomas (36%) in 5 of 7 patients (71%). The median decrease in CSA was -10% (range -3%--25%). One meningioma (7%) progressed and the remaining (93%) had stable disease. CONCLUSIONS: Bevacizumab may slow or reverse the growth of some NF-related meningiomas. However, we have previously reported a fatal case of intracerebral hemorrhage following bevacizumab in NF2 patients, wherefore, this effect needs to be balanced carefully against the risk of side effects.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Evaluación de Resultado en la Atención de Salud / Neurofibromatosis 2 / Inhibidores de la Angiogénesis / Bevacizumab / Neoplasias Meníngeas / Meningioma Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Neurosci Año: 2016 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Evaluación de Resultado en la Atención de Salud / Neurofibromatosis 2 / Inhibidores de la Angiogénesis / Bevacizumab / Neoplasias Meníngeas / Meningioma Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Neurosci Año: 2016 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido